Media headlines about Cryolife (NYSE:CRY) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cryolife earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.2938745478537 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several research analysts have weighed in on CRY shares. Canaccord Genuity reissued a “buy” rating and set a $25.00 price objective on shares of Cryolife in a report on Wednesday, January 3rd. Northland Securities reaffirmed a “buy” rating and issued a $23.50 price target on shares of Cryolife in a report on Monday, November 13th. Finally, Zacks Investment Research raised shares of Cryolife from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $24.83.

Cryolife (NYSE:CRY) opened at $18.75 on Friday. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. The company has a market cap of $677.63, a PE ratio of 66.96 and a beta of 0.75.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with's FREE daily email newsletter.